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ABSTRACT
A young boy with no premorbids was admitted with fever, fits and psychosis. His initial investigations including 
cerebrospinal fluid (CSF) routine examination, electroencephalogram(EEG) and MRI brain with contrast were normal. 
His autoimmune encephalitis panel revealed positive voltage gated potassium channel(VGKC) antibodies,
anti -leucine rich glioma inactivated 1 antibody (LG1) group and was give five doses of methylprednisolone and five 
sessions of plasmapheresis. Psychiatric symptoms took one month to respond. He had a complete recovery. 
Autoimmune limbic encephalitis should be diagnosed promptly in young patient with fit, psychosis and a high index of 
suspicion should be kept as initial work up including MRI brain with contrast, EEG and CSF examination can be normal 
in such patients.
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C A S E  R E P O R T
INTRODUCTION: Limbic encephalitis (LE) is an 
uncommon neurological disorder characterized by a 
subacute and progressive altered consciousness, 
memory disturbance, and recurrent seizures1. We 
present a case of anti LG1 associated limbic 
encephalitis in a young patient who had a very typical 
presentation and excellent outcome.
Case summary
A 21 years old boy with no premorbids, presented to us 
with one week’s history of altered behaviour, fever and 
fits. One day prior to it he developed lethargy, 
headache, generalised body aches and decreased 
appetite. Fever was high grade intermittent associated 
with rigors recorded up to 104. Following it he 
developed altered behaviour, irritability, and fits which 
were generalised tonic clonic (GTC), with tongue bite 
and urinary incontinence. Along with GTC he also 
developed dystonic posturing of neck and arching of 
body. On examination, he was confused, there was no 
neck stiffness and there was no focal deficit. Initially he 
was investigated and treated on the lines of 
meningoencephalitis. Investigations revealed normal 
Computerised tomography (CT) brain, normal white 
blood cells, C reactive protein. CSF routine examination 
was normal (<5 cells, protein 19.8mg/dl, glucose 
56mg/dl). Blood cultures, malarial parasite smears, 
urine routine examination were normal. He was started 
on injection Acyclovir along with injection Meropenem 
on day 1, his fever settled after 48hours but the fits 
persisted. EEG was done which came out normal. MRI 
brain with contrast was also normal as shown in figure 
1. CSF Herpes Simplex Virus PCR also came back 
negative. His repeat EEG showed extreme delta 
brushes with some degree of background slowing as 
shown in figure2.
Figure 1. 
MRI brain with 
contrast showing
no abnormality.
Figure 2. EEG showing extreme delta brushes over 
a slow background.
His fits persisted and were refractory to treatment. As 
he was a young patient with refractory seizures and 
psychiatric manifestations so autoimmune encephalitis 
profile was also sent, which came out positive for 
Voltage gated potassium channel (VGKC) antibodies 
(LG1 group) in serum. The patient was started on 
intravenous high dose steroids in form of intravenous 
methylprednisolone in dose of one gram daily, but the 
fits persisted, his antiepileptics were escalated to four 
antiepileptics including valproate sodium, levitiracetam 
,lacosamide and phenytoin at about near maximal 
doses but the fits did not respond. Along with GTC fits 
he had facial twitching, faciobrachial dystonic seizures. 
As seizures were refractory and patient was not 
improving, he was started plasma exchange (PLEX), he 
had five sessions of plasma exchange each session 
being 50ml/kg.  After PLEX fits were controlled but 
neuropsychiatric symptoms persisted. He was started 
on antipsychotics and was given good nursing care. He 
was also worked up for other causes, like autoimmune 
profile, CT chest abdomen and pelvis came back 
negative. Anti N-methyl-d aspartate (NMDA) antibodies 
and other autoimmune encephalitis panel antibodies 
also came back negative. Paraneoplastic antibodies 
panel also came back negative. After two weeks of 
completion of PLEX patient started improving, fits 
settled, antiepileptics were tapered off gradually, 
antipsychotic were also gradually withdrawn. At one 
month followup patient had no cognitive deficits.
Discussion
Limbic encephalitis with LG 1 antibodies is a rare 
neuroimmunological disorder characterized by cognitive 
decline, psychiatric disturbances and seizures 
(distinctively faciobrachial dystonic seizures) in 
association with detection of LG1 antibodies in serum 
or CSF. Additional features are hallucinations, sleep 
cycle disturbances, agitation, and delusions2.
Faciobrachial dystonic seizures(FDSP) are highly 
distinctive seizures associated with VGKC complex 
antibodies, almost always in the LGI 1 subtype. Every 
FBDS is characterized by a dystonic posturing of the 
arm, both proximally and distally, and may involve also 
the ipsilateral face and less commonly, the trunk and 
the ipsilateral leg. They carry a high chance of 
developing VGKC LE, and their recognition should 
prompt consideration of immunotherapies2. 
Hyponatremia is present in about 60% of patients2. 
Serum sodium are often reduced in FBDS patients 
presenting also with cognitive impairment but they were 
repeatedly normal in our patient.
Although there are currently no agreed-upon diagnostic 
criteria for limbic encephalitis; a useful set of criteria for 
both paraneoplastic limbic encephalitis (PLE) and 
non-paraneoplastic limbic encephalitis( nPLE) was 
proposed by Bien and Elger in 2007 as shown in table 
13. 
TABLE 1. Bien and Elger’s Diagnostic Criteria for 
Limbic Encephalitis3.
Anti LG1 encephalitis is most often non-paraneoplastic. 
Neoplasms are detected only in a minority of 
seropositive patients for VGKC complex and do not 
significantly associate with Caspr 2 or LG12. A normal 
brain MRI does not exclude these cases. MRI brain was 
also normal in our patient and one should not rely on 
MRI to diagnosis these conditions. Similarly, MRI does 
not differentiate between infective and these 
autoimmune etiologies4. Because of the nature and 
complexity of non- paraneoplastic limbic encephalitis 
(nPLE), a greater awareness of this condition is 
warranted, particularly among psychiatrists in order to 
establish the correct diagnosis and commence early 
treatment as VGKC complex antibody-associated non 
paraneoplastic limbic encephalitis is potentially 
treatable and has good response to early initiated 
immunotherapy2.
Conclusion
Autoimmune encephalitis should always be suspected 
in a young patient with neuropsychiatric problems, fits 
and movement disorders. CSF routine examination, 
EEG, even MRI brain with contrast could all be normal 
in a patient with autoimmune encephalitis and a high 
index of suspicion should be kept to diagnose and 
promptly treat such conditions.
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Figure 2. EEG showing extreme delta brushes over 
a slow background.
His fits persisted and were refractory to treatment. As 
he was a young patient with refractory seizures and 
psychiatric manifestations so autoimmune encephalitis 
profile was also sent, which came out positive for 
Voltage gated potassium channel (VGKC) antibodies 
(LG1 group) in serum. The patient was started on 
intravenous high dose steroids in form of intravenous 
methylprednisolone in dose of one gram daily, but the 
fits persisted, his antiepileptics were escalated to four 
antiepileptics including valproate sodium, levitiracetam 
,lacosamide and phenytoin at about near maximal 
doses but the fits did not respond. Along with GTC fits 
he had facial twitching, faciobrachial dystonic seizures. 
As seizures were refractory and patient was not 
improving, he was started plasma exchange (PLEX), he 
had five sessions of plasma exchange each session 
being 50ml/kg.  After PLEX fits were controlled but 
neuropsychiatric symptoms persisted. He was started 
on antipsychotics and was given good nursing care. He 
was also worked up for other causes, like autoimmune 
profile, CT chest abdomen and pelvis came back 
negative. Anti N-methyl-d aspartate (NMDA) antibodies 
and other autoimmune encephalitis panel antibodies 
also came back negative. Paraneoplastic antibodies 
panel also came back negative. After two weeks of 
completion of PLEX patient started improving, fits 
settled, antiepileptics were tapered off gradually, 
antipsychotic were also gradually withdrawn. At one 
month followup patient had no cognitive deficits.
Discussion
Limbic encephalitis with LG 1 antibodies is a rare 
neuroimmunological disorder characterized by cognitive 
decline, psychiatric disturbances and seizures 
(distinctively faciobrachial dystonic seizures) in 
association with detection of LG1 antibodies in serum 
or CSF. Additional features are hallucinations, sleep 
cycle disturbances, agitation, and delusions2.
Faciobrachial dystonic seizures(FDSP) are highly 
distinctive seizures associated with VGKC complex 
antibodies, almost always in the LGI 1 subtype. Every 
FBDS is characterized by a dystonic posturing of the 
arm, both proximally and distally, and may involve also 
the ipsilateral face and less commonly, the trunk and 
the ipsilateral leg. They carry a high chance of 
developing VGKC LE, and their recognition should 
prompt consideration of immunotherapies2. 
Hyponatremia is present in about 60% of patients2. 
Serum sodium are often reduced in FBDS patients 
presenting also with cognitive impairment but they were 
repeatedly normal in our patient.
Although there are currently no agreed-upon diagnostic 
criteria for limbic encephalitis; a useful set of criteria for 
both paraneoplastic limbic encephalitis (PLE) and 
non-paraneoplastic limbic encephalitis( nPLE) was 
proposed by Bien and Elger in 2007 as shown in table 
13. 
TABLE 1. Bien and Elger’s Diagnostic Criteria for 
Limbic Encephalitis3.
Anti LG1 encephalitis is most often non-paraneoplastic. 
Neoplasms are detected only in a minority of 
seropositive patients for VGKC complex and do not 
significantly associate with Caspr 2 or LG12. A normal 
brain MRI does not exclude these cases. MRI brain was 
also normal in our patient and one should not rely on 
MRI to diagnosis these conditions. Similarly, MRI does 
not differentiate between infective and these 
autoimmune etiologies4. Because of the nature and 
complexity of non- paraneoplastic limbic encephalitis 
(nPLE), a greater awareness of this condition is 
warranted, particularly among psychiatrists in order to 
establish the correct diagnosis and commence early 
treatment as VGKC complex antibody-associated non 
paraneoplastic limbic encephalitis is potentially 
treatable and has good response to early initiated 
immunotherapy2.
Conclusion
Autoimmune encephalitis should always be suspected 
in a young patient with neuropsychiatric problems, fits 
and movement disorders. CSF routine examination, 
EEG, even MRI brain with contrast could all be normal 
in a patient with autoimmune encephalitis and a high 
index of suspicion should be kept to diagnose and 
promptly treat such conditions.
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Figure 2. EEG showing extreme delta brushes over 
a slow background.
His fits persisted and were refractory to treatment. As 
he was a young patient with refractory seizures and 
psychiatric manifestations so autoimmune encephalitis 
profile was also sent, which came out positive for 
Voltage gated potassium channel (VGKC) antibodies 
(LG1 group) in serum. The patient was started on 
intravenous high dose steroids in form of intravenous 
methylprednisolone in dose of one gram daily, but the 
fits persisted, his antiepileptics were escalated to four 
antiepileptics including valproate sodium, levitiracetam 
,lacosamide and phenytoin at about near maximal 
doses but the fits did not respond. Along with GTC fits 
he had facial twitching, faciobrachial dystonic seizures. 
As seizures were refractory and patient was not 
improving, he was started plasma exchange (PLEX), he 
had five sessions of plasma exchange each session 
being 50ml/kg.  After PLEX fits were controlled but 
neuropsychiatric symptoms persisted. He was started 
on antipsychotics and was given good nursing care. He 
was also worked up for other causes, like autoimmune 
profile, CT chest abdomen and pelvis came back 
negative. Anti N-methyl-d aspartate (NMDA) antibodies 
and other autoimmune encephalitis panel antibodies 
also came back negative. Paraneoplastic antibodies 
panel also came back negative. After two weeks of 
completion of PLEX patient started improving, fits 
settled, antiepileptics were tapered off gradually, 
antipsychotic were also gradually withdrawn. At one 
month followup patient had no cognitive deficits.
Discussion
Limbic encephalitis with LG 1 antibodies is a rare 
neuroimmunological disorder characterized by cognitive 
decline, psychiatric disturbances and seizures 
(distinctively faciobrachial dystonic seizures) in 
association with detection of LG1 antibodies in serum 
or CSF. Additional features are hallucinations, sleep 
cycle disturbances, agitation, and delusions2.
Faciobrachial dystonic seizures(FDSP) are highly 
distinctive seizures associated with VGKC complex 
antibodies, almost always in the LGI 1 subtype. Every 
FBDS is characterized by a dystonic posturing of the 
arm, both proximally and distally, and may involve also 
the ipsilateral face and less commonly, the trunk and 
the ipsilateral leg. They carry a high chance of 
developing VGKC LE, and their recognition should 
prompt consideration of immunotherapies2. 
Hyponatremia is present in about 60% of patients2. 
Serum sodium are often reduced in FBDS patients 
presenting also with cognitive impairment but they were 
repeatedly normal in our patient.
Although there are currently no agreed-upon diagnostic 
criteria for limbic encephalitis; a useful set of criteria for 
both paraneoplastic limbic encephalitis (PLE) and 
non-paraneoplastic limbic encephalitis( nPLE) was 
proposed by Bien and Elger in 2007 as shown in table 
13. 
TABLE 1. Bien and Elger’s Diagnostic Criteria for 
Limbic Encephalitis3.
Anti LG1 encephalitis is most often non-paraneoplastic. 
Neoplasms are detected only in a minority of 
seropositive patients for VGKC complex and do not 
significantly associate with Caspr 2 or LG12. A normal 
brain MRI does not exclude these cases. MRI brain was 
also normal in our patient and one should not rely on 
MRI to diagnosis these conditions. Similarly, MRI does 
not differentiate between infective and these 
autoimmune etiologies4. Because of the nature and 
complexity of non- paraneoplastic limbic encephalitis 
(nPLE), a greater awareness of this condition is 
warranted, particularly among psychiatrists in order to 
establish the correct diagnosis and commence early 
treatment as VGKC complex antibody-associated non 
paraneoplastic limbic encephalitis is potentially 
treatable and has good response to early initiated 
immunotherapy2.
Conclusion
Autoimmune encephalitis should always be suspected 
in a young patient with neuropsychiatric problems, fits 
and movement disorders. CSF routine examination, 
EEG, even MRI brain with contrast could all be normal 
in a patient with autoimmune encephalitis and a high 
index of suspicion should be kept to diagnose and 
promptly treat such conditions.
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